Efficacy of different schedules in the management of chronic hepatitis C with interferon-alpha
- PMID: 9667801
- DOI: 10.3109/07853899808999406
Efficacy of different schedules in the management of chronic hepatitis C with interferon-alpha
Abstract
The best results in terms of clinical remission in chronic hepatitis C are achieved by interferon (IFN)-alpha treatment. We studied 255 patients affected by chronic hepatitis C infection (HCV) and divided into 3 groups. A different IFN-alpha therapeutic schedule was adopted in each group: A) 3 million units (MU) three times per week for 6 months; B) 3 MU three times per week for 12 months; C) 6 MU three times per week for 6 months. A sustained biohumoural and virological remission was observed in only 14.5% of the patients included in group A, in 21.6% of the patients included in group B and in 8% of the patients included in group C. The adoption of more aggressive therapeutic regimens did not offer an improvement in response or patient compliance. At present, the long term efficacy of treatment may be evaluated on the basis of both biochemical and virological data.
Similar articles
-
Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group.Am J Gastroenterol. 2000 Oct;95(10):2928-35. doi: 10.1111/j.1572-0241.2000.02321.x. Am J Gastroenterol. 2000. PMID: 11051370 Clinical Trial.
-
Use of high-dose interferon in the treatment of chronic hepatitis C.Semin Liver Dis. 1999;19 Suppl 1:25-33. Semin Liver Dis. 1999. PMID: 10349690 Review.
-
Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).Hepatology. 1998 Dec;28(6):1680-6. doi: 10.1002/hep.510280631. Hepatology. 1998. PMID: 9828235 Clinical Trial.
-
[Chronic hepatitis C--therapeutic modalities for interferon failure].Praxis (Bern 1994). 1998 Oct 14;87(42):1413-20. Praxis (Bern 1994). 1998. PMID: 9824949 Review. German.
-
Comparison of two interferon alfa treatment regimens characterized by an early virological response in patients with chronic hepatitis C.Am J Gastroenterol. 1998 Feb;93(2):192-6. doi: 10.1111/j.1572-0241.1998.00192.x. Am J Gastroenterol. 1998. PMID: 9468240 Clinical Trial.
Cited by
-
L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-α 2b plus ribavirin.World J Gastroenterol. 2011 Oct 21;17(39):4414-20. doi: 10.3748/wjg.v17.i39.4414. World J Gastroenterol. 2011. PMID: 22110268 Free PMC article. Clinical Trial.
-
L-carnitine treatment reduces steatosis in patients with chronic hepatitis C treated with alpha-interferon and ribavirin.Dig Dis Sci. 2008 Apr;53(4):1114-21. doi: 10.1007/s10620-007-9983-1. Epub 2007 Oct 16. Dig Dis Sci. 2008. PMID: 17939042 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials